The Sysmex CS-5100 coagulation analyzer offers comparable analytical performance and excellent throughput capabilities  by Flieder, T. et al.
Contents lists available at ScienceDirect
Practical Laboratory Medicine
journal homepage: www.elsevier.com/locate/plabm
The Sysmex CS-5100 coagulation analyzer oﬀers comparable
analytical performance and excellent throughput capabilities
T. Flieder1, T. Gripp1, C. Knabbe, I. Birschmann⁎
Institute for Laboratory and Transfusion Medicine, Heart and Diabetes Center, Ruhr University Bochum, Georgstrasse 11, 32545 Bad
Oeynhausen, Germany
A R T I C L E I N F O
Keywords:
Coagulation analyzer
CS-5100
Evaluation
Automation
A B S T R A C T
Objectives: This study compared the new high-volume blood coagulation analyzer Sysmex CS-
5100 System™ (Siemens Healthcare Diagnostics, Erlangen, Germany) to the mid-volume blood
coagulation analyzer Sysmex CS-2000i System™ (Siemens) for analytical performance.
Additionally, the operational performance of the Sysmex CS-5100 System was compared with
the blood coagulation analyzer ACL TOP 700 (Instrumentation Laboratory, Werfen Group,
Kirchheim bei Munchen, Germany).
Materials and methods: We compared the Sysmex CS-5100 to the Sysmex CS-2000i and the
ACL TOP analyzer for routine coagulation, chromogenic and immunological assays. Imprecision
studies were performed for the Sysmex CS-5100 and Sysmex CS-2000i systems. A throughput
and STAT analysis comparison of the CS-5100 and the ACL TOP was performed. A stress test
was performed to characterize the robustness and the error rate of the CS-5100. We also
performed correlation analysis between the CS-5100 and the CS-2000i or the ACL TOP in the
measurement of patients’ samples.
Results: The inter-assay precision using the CS systems was impressive (inter-assay CV
generally < 3.5%) and the correlation between the two Sysmex analyzers was excellent. In the
throughput study, the CS-5100 completed the measurement of 100 samples (210 results) in less
than 49 min.
Conclusions: Our results demonstrated that the CS-5100 is a robust high-throughput analyzer,
well-suited for coagulation laboratories.
1. Introduction
Current requirements in the hemostasis laboratory include optimal diagnostic performance, improved quality management, and
eﬃcient work-ﬂow. The high-volume blood coagulation analyzer Sysmex CS-5100 System™ (Siemens Healthcare Diagnostics,
Erlangen, Germany) is fully automated and has been developed for routine coagulation diagnostics in large hospitals.
The investigation of hemostasis has always been an important aspect of laboratory diagnostics. With the growing number of
samples which a laboratory must handle, a fast, precise and robust analyzer is essential. Furthermore, any new analyzer should
require minimal operational and maintenance time, and have a small sample and dead volume in order to analyze pediatric samples.
In modern laboratories most analyzers used for clinical chemistry, hematology and hemostaseology are automated for shorter
turn-around-time (TAT) (especially for samples from the emergency room and intensive care unit) and to minimize the personnel
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needed to operate them Any new coagulation analyzer must be compatible with such systems for measuring the standard parameters
(PT, PTT, ﬁbrinogen, antithrombin, d-dimer). In particular, in laboratories associated with blood transfusion services, the precise
measurement of single-factor activity is necessary to obtain all the oﬃcial licenses required. The system should also perform more
speciﬁc assays e.g. Protein C, Protein S, von Willebrand assays.
The operation of the analyzer and the software must be simple and intuitive because the technical staﬀmust be able to work with
the various analyzers (e.g. clinical chemistry and hemostaseology) concurrently.
2. Materials and methods
2.1. Sample collection and preparation
Leftover citrated plasma from patient samples was used to evaluate the system. Blood was collected in 2.9 mL tubes containing
290 µL sodium citrate (100 mmol/L) (KABE Labortechnik GmbH, Nümbrecht, Germany). Blood was centrifuged for 10 min at
3000×g for prothrombin time (PT), partial thromboplastin time (PTT), antithrombin (AT), ﬁbrinogen (Fib) and D-dimer. For
speciﬁc hemostaseological tests (factor II (FII), factor V (FV), factor VII (FVII), factor VIII (FVIII), factor IX (FIX), factor X (FX),
factor XI (FXI), factor (FXII), factor XIII (FXIII), protein C (PC), von Willebrand factor antigen (VWF Ag), von Willebrand factor
activity (VWF Ac), activated protein C-resistance (APC-resistance)) plasma was again centrifuged at 3000×g for 10 min (room
temperature), frozen at −20 °C for a maximum of one week and analyzed in batches.
2.2. The analyzer
The Sysmex CS-5100 System is a fully automated, computer-interfaced coagulation analyzer intended for in vitro diagnostic use.
The analyzer has 36 incubation wells and 20 measurement channels. The Sysmex system is able to perform clotting, chromogenic
Table 1
Reagents and calibrators used on the CS-5100/CS-2000i analyzers for the comparison study.
Siemens Healthcare Diagnostics Products GmbH
Test Reagent/Calibrator/Control
PT Thromborel® S/ PT Multi Calibrator/Control Plasma N, Control Plasma P, Dade® Ci-Trol® 2
Dade Innovin®/ PT Multi Calibrator/Control Plasma N, Control Plasma P, Dade Ci-Trol 2
APTT Dade Actin® FSL/ - /Control Plasma N, Dade Ci-Trol 2
Pathromtin® SL/ - /Control Plasma N, Dade Ci-Trol 2
Fib Dade Thrombin-Reagent/Standard Human Plasma/ Control Plasma N, Control Plasma P
FII/ FV/ FVII/ FX Dade Innovin/ Standard Human Plasma/Control Plasma N, Control Plasma P
FVIII/ FIX/ FXI/ FXII Dade Actin FSL/Standard Human Plasma/Control Plasma N, Control Plasma P
F XIII Berichrom® FXIII/Standard Human Plasma/Control Plasma N, Control Plasma P
AT INNOVANCE® Antithrombin/Standard Human Plasma/Control Plasma N, Control Plasma P
D-Dimer INNOVANCE D-Dimer/INNOVANCE D-Dimer Cal/INNOVANCE D-Dimer Control 1 + 2
VWF Ac INNOVANCE VWF Ac/Standard Human Plasma/ Control Plasma N, Control Plasma P
VWF Ag von Willebrand Antigen/ Standard Human Plasma/ Control Plasma N, Control Plasma P
TT Test Thrombin Reagent/ - /Control Plasma N, Control Plasma P
PC Protein C Reagent/Standard Human Plasma/ Control Plasma N, Control Plasma P
APC ProC® Ac R/ - /Control Plasma N, ProC Control Plasma
Instrumental Laboratory
Test Reagent/Calibrator/Control
PT HemosIL Recombi PlasTin 2 G/HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Low Abnormal Control
APTT HemosIL SynthASil/ - /HemosIL Normal Control, HemosIL Low Abnormal Control
APTT-SP (liquid)/ - /HemosIL Normal Control, HemosIL Low Abnormal Control
Fib HemosIL Q.F.A. Thrombin (Bovine)/HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Low Abnormal Control
FII/ FV/ FVII/ FX HemosIL Factor II/ V/ VII/ X deficient plasma/HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Special Test
Control Level 2
FVIII/ FIX/ FXI/ FXII HemosIL Factor VIII/ IX/ XI/ XII deficient plasma/HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Special
Test Control Level 2
F XIII HemosIL Factor XIII Antigen/ HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Special Test Control Level 2
AT HemosIL Antithrombin/ HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Low Abnormal Control
D-Dimer HemosIL D-Dimer HS 500/ HemosIL D-Dimer HS 500 Calibrator/HemosIL D-Dimer HS 500 Controls
VWF Ac HemosIL VWF Ac/HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Special Test Control Level 2
VWF Ag HemosIL VWF Ag/HemosIL Calibration Plasma/HemosIL Normal Control, HemosIL Special Test Control Level 2
TT HemosIL Thrombinzeit/ - /HemosIL Normal Control, HemosIL Low Abnormal Control
PC HemosIL ProC/ HemosIL Calibration Plasma/ HemosIL Normal Control, HemosIL Special Test Control Level 2
APC HemosIL Factor V Leiden/ - /HemosIL APC Control Plasma Level 1 + 2
PT: prothrombin time; APTT: activated partial thromboplastin time; Fib: fibrinogen, FII: factor II; FV: factor V; FVII factor VII; FVIII: factor VIII; FIX: factor IX; FX:
factor X, FXI: factor XI; FXII: factor FXII; FXIII: factor XIII; PC: protein C; VWF Ag: von Willebrand factor antigen; VWF Ac: von Willebrand factor activity; APC-
resistance: activated protein C-resistance.
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and immunological tests. The absorbance measurement unit uses a halogen lamp with 340, 405, 575, 660, and 800 nm wavelengths.
The analyzer can hold 10 racks with 10 samples per rack, with capability to mix primary tubes from diﬀerent manufacturers on
the same rack at the same time. It has an additional cap-piercing sample arm, which processes capped and uncapped sample tubes.
Up to 40 reagents can be stored on board using the rack system, which are all cooled at 10 °C ± 2 °C. Five extra positions at ambient
temperature are dedicated for buﬀer or rinse solution. Additionally, there are ﬁve STAT positions which can be loaded continuously;
the analyzer will immediately start measuring the samples. Samples, controls and reagents are identiﬁed by barcode readers. As
Control plasma can be included in the reagent area, so measurement of controls can be performed at any time, for instance when a
new vial of reagent is used. It is also possible to run the control from a 4 mL cup loaded on a sample rack to avoid reducing the
number of reagent positions available.
During measurement, it is possible to load cuvettes (up to 1000) and samples continuously. If reagents need to be changed, the
system will stop the run at the next feasible time.
Sophisticated software algorithms record, monitor, and check reaction kinetics to determine the correct clotting time. In
addition, the system provides an overview of all loaded reagents showing the number of remaining tests and the time since the
reagent was uploaded into the analyzer. Connection to the system manager is optional.
The analyzer performs an automatic hemolysis, icterus and lipemia check with a preanalytical scan of patient samples performed
at two wavelengths (575 nm and 660 nm). A primary tube sample volume check identiﬁes insuﬃcient sample volume.
2.3. Reagents
The reagents and calibrators used on the CS-5100 and CS-2000i for this study are listed in Table 1. All assays were performed
according to the manufacturers’ speciﬁcations and standard laboratory methods.
2.4. Methods
The study was designed in order to evaluate the Sysmex CS-5100 in terms of hardware/software quality and in routine use.
Therefore, patient samples were measured with both the CS-5100 and CS-2000i as well as the ACL TOP. Several aspects of the study,
e.g. test samples and storage were performed based on the CLSI EP9-A2 guidelines (CLSI, Wayne, PA, USA), which we followed.
After independently training two technicians, a robustness test of both Sysmex analyzers was performed over ﬁve weeks. During this
period, an average of 128 samples a day (range 36–186) and a total of 3093 samples was analyzed. The same procedure was
performed by the second technician for two more weeks, analyzing an average of 130 (range 67–243) samples per day and 1684
samples in total.
Imprecision was determined using the following commercial quality control materials at diﬀerent concentration levels: Control
Plasma N (CPN), Control Plasma P (CPP), Dade Ci-Trol 2 (Citrol 2), INNOVANCE D-Dimer Control 1, INNOVANCE D-Dimer
Control 2 (Table 1). All control preparations were obtained from Siemens Healthcare Diagnostics Products GmbH (Marburg,
Germany). The coeﬃcient of variation (CV) for each material was calculated based on the daily results of measured samples.
A stress test was performed over three days. On day one the CS-5100 was used for nonstop measurement over ﬁve hours with the
Table 2A
Inter-assay precision of the CS-5100 and CS-2000i analyzers for routine tests.
CS5100 CS2000i
Test Control Unit n Mean±SD CV (%) n Mean±SD CV (%)
PT (Dade INNOVIN) N % 28 85.5 ± 2.17 2.54 25 86 ± 2.57 2.99
PT (Dade INNOVIN) P % 25 36.4 ± 0.54 1.47 28 36.3 ± 0.69 1.89
INR N 28 1.07 ± 0.01 0.92 25 1.07 ± 0.02 1.45
INR P 25 1.81 ± 0.03 1.4 28 1.81 ± 0.03 1.65
PT (Thromborel S) N % 32 80.8 ± 2.83 3.51 33 87.2 ± 4.14 4.75
PT (Thromborel S) P % 33 40.5 ± 1.18 2.91 32 41.3 ± 2.11 5.1
INR N 32 1.11 ± 0.02 1.99 33 1.07 ± 0.03 2.65
INR P 33 1.80 ± 0.05 2.61 32 1.77 ± 0.08 4.52
APTT (Dade Actin FSL) N s 33 27.1 ± 0.17 0.63 33 27 ± 0.26 0.95
APTT (Dade Actin FSL) C2 s 33 48.7 ± 0.66 1.35 33 48.7 ± 0.67 1.38
APTT (Pathromtin SL) N s 32 31.5 ± 0.85 2.7 32 31.9 ± 0.39 1.23
APTT (Pathromtin SL) C2 s 32 62.4 ± 0.65 1.04 32 62.7 ± 1.01 1.61
Fibrinogen N g/L 54 2.43 ± 0.06 2.29 53 2.36 ± 0.09 3.64
Fibrinogen P g/L 53 0.81 ± 0.02 2.15 54 0.79 ± 0.03 3.34
Antithrombin N % 50 94.5 ± 2.15 2.28 48 95.4 ± 3.14 3.29
Antithrombin P % 48 31.9 ± 1.01 3.15 50 33.3 ± 1.44 4.33
INNOVANCE D-Dimer D1 mg/L 21 0.35 ± 0.01 4.26 21 0.32 ± 0.03 10.74
INNOVANCE D-Dimer D2 mg/L 23 2.58 ± 0.29 11.41 22 2.55 ± 0.2 10.43
Abbreviations as in Table 1. N=Control Plasma N; P=Control Plasma P; C2=Dade Citrol 2, D1=D-Dimer control 1; D2=D-Dimer control 2. SD = standard deviation,
CV=coefficient of variation.
T. Flieder et al. Practical Laboratory Medicine 6 (2016) 38–47
40
analysis of routine tests and a small number of speciﬁc hemostaseological ones. STAT samples were inserted randomly in the CS-
5100 during the stress test. During the test, under ﬁlled bottles were used to induce a change of reagent vials. As primary tubes,
pediatric tubes, and sample cups can be loaded onto the same rack, this was additionally tested under stress conditions. One the
second day the analyzer was continuously loaded with samples over ﬁve hours with routine preparation of the analyzer. The
throughput of the CS-5100 and ACL TOP was evaluated using the same 100 routine samples with request for PT (n=100), PTT
(n=80), AT (n=20) and d-dimer (n=10). STAT capability was determined by the processing time of two STAT samples for the same
four assays. Finally, on day three the barcode reader was tested using unclear barcodes, e.g. wet or damaged barcodes, on various
tubes. A 24-h test was also conducted in order to simulate a routine day including reagent changes, maintenance and a shutdown of
the system during which time samples were continuously delivered for measurement.
2.5. Statistical evaluation
The method comparison study data were evaluated by Siemens Healthcare Diagnostics Products GmbH using the statistical
software SAS V9.1. Passing-Bablok regression analysis as well as Bland-Altman analysis were performed. For Passing Bablok
regression we deemed an acceptable comparison to be a slope of 1.0 ± 0,1 and a correlation coeﬃcient r > 0,95.
3. Results
3.1. Inter-assay precision
As shown in Table 2A, the inter-assay CVs (PT, PTT, Fib, AT) were below 3.51% for the parameters measured in controls (normal
and pathological range) using the CS-5100, consistent with previous studies [1,2]. The same was true for the CS-2000i, with inter-
assay CVs below 5.1%. The CV for speciﬁc coagulation parameters such as FVIII, FXIII, VWF Ag, VWF Ac was also calculated when a
minimum of 6 analyses of controls had been performed (Table 2B). Exceptionally, D-dimer measurement showed a higher CV for the
pathological control (11.41%) whereas the normal control had a lower CV of 4.26%.
3.2. Method comparison study
The results of the correlation study between the CS-5100, CS-2000i and ACL TOP are shown for PT, PTT, Fib and AT Fig. 1(A–D)
and for PT, PTT, Fib and AT in Tables 3A, 3B. In addition, measurements of various coagulation factors were performed according to
the individual requests. However, in view of the low numbers (n < 40), no further statistical analysis was conducted..
Table 2B
Inter-assay precision of the CS-5100 and CS-2000i analyzers for special coagulation parameters.
Test Control Unit n CS5100 n CS2000i
Mean±SD CV (%) Mean±SD CV (%)
F II N % 8 89.5 ± 2.55 2.86 8 93.5 ± 2.85 3.04
P % 8 31.3 ± 0.9 2.88 8 31 ± 0.84 2.72
F V N % 8 92.2 ± 2.53 2.75 8 88.8 ± 5.79 6.52
P % 8 29.1 ± 3.98 3.98 8 29.6 ± 2.15 7.27
F VII N % 6 83.5 ± 2.92 3.5 6 86.6 ± 4.67 5.39
P % 6 34.8 ± 0.75 2.15 6 35.6 ± 1.03 2.89
F VIII N % 19 87.2 ± 3.13 3.59 19 89.6 ± 6.22 6.94
P % 18 27.3 ± 1.13 4.13 21 27.3 ± 2.48 9.08
F IX N % 8 90.9 ± 2.4 2.64 15 83.8 ± 7.2 8.59
P % 8 31.7 ± 2.18 2.18 9 28.6 ± 2.68 9.37
F X N % 6 84.4 ± 2.86 3.38 6 92.3 ± 5.25 5.69
P % 6 31.5 ± 0.97 3.08 6 31.5 ± 1.2 3.81
F XI N % 6 92.6 ± 3.46 3.74 6 101.2 ± 3.85 3.81
P % 6 29.1 ± 0.24 0.84 6 28.7 ± 1.25 4.37
F XII N % 6 90 ± 4.05 4.51 6 93 ± 5.82 6.26
P % 8 32.7 ± 3.84 11.75 6 30.1 ± 3.1 10.33
F XIII N % 10 85.1 ± 2.26 2.65 15 81.2 ± 7.53 9.28
P % 12 26.0 ± 1.56 6 13 20.7 ± 2.76 10.89
VWF Ag med N % 16 109.9 ± 2.20 2 16 114.7 ± 2.27 1.98
P % 16 40.1 ± 1.13 2.82 16 40.9 ± 1.20 2.93
INNOVANCE VWF Ac med N % 14 92.6 ± 1.95 2.11 14 97.7 ± 6.43 6.59
P % 14 28.9 ± 0.47 1.62 14 28.2 ± 1.37 4.88
Protein C N % 8 95.2 ± 7.19 7.55 8 96 ± 7.6 7.92
P % 8 32.4 ± 1.97 6.08 8 35.4 ± 3.55 10.02
APC resistance (ratio) N % 8 3.16 ± 0.13 4.17 10 3.12 ± 0.15 4.93
P % 8 1.15 ± 0.02 1.64 8 1.17 ± 0.02 1.33
Abbreviations as in Table 1. N= Control Plasma N; P = Control Plasma P. SD = standard deviation, CV = coeﬃcient of variation.
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The agreement between results obtained from diﬀerent analyzers is demonstrated for PT, PTT, Fib and AT in diﬀerence-plots
according to Bland and Altman (Fig. 2A–D). A complete list of all results is shown in Table 4..
The small diﬀerences between the two analyzers are demonstrated using Bland-Altman plots which show that consideration of
the diﬀerences is not essential for making clinical decisions. The Bland-Altman plot of PTT using Actin FSL reagent, for example,
showed a mean time diﬀerence of −0.167 s with a ± 2SD range of −2.042 to 1.708 s. This is clearly a strong indication of the good
correlation between the two analyzers where no clinically relevant diﬀerences could be observed. Furthermore, the plots reveal no
systematic bias and, as shown in Fig. 2A–D, there are also no deviations between the means of the two systems. However, although
the results obtained from comparison of the two CS systems showed excellent correlation, small diﬀerences could be detected when
we compared the ACL TOP to the CS-5100.
3.3. Interference
Analytical interference with spectrophotometric methods occurs with hemolysis, bilirubin and lipids with laboratory assays. As a
consequence, the altered results may lead to inappropriate further tests, incorrect interpretation, incorrect diagnosis and potentially
needless intervention and unfavorable outcome for patients [3]. The hemolysis, icterus and lipemia (HIL) check detects these
potential interferences with using a photometric absorbance check on patient samples at relevant wavelengths.
To verify the ability of the CS-5100 to detect hemolytic and lipemic samples, two panels consisting of 37 and 4 samples,
respectively, were identiﬁed by visual assessment and were quantiﬁed for free hemoglobin and triglycerides. As most of the
hemostatic assays were not aﬀected signiﬁcantly by bilirubin, no further analyses of icteric samples were carried out in the study.
From the hemolytic sample panel 33 samples were conﬁrmed by measurement of free hemoglobin > 50 mg/dL. This
concentration has been shown to inﬂuence various spectrophotometric assays. The CS-5100 ﬂagged 32 samples of these samples
correctly (97%). Three samples were ﬂagged but had free hemoglobin concentrations below 50 mg/dL (31 mg/dL, 39 mg/dL and
43 mg/dL) and one sample with a free hemoglobin concentration of 60 mg/dL was not ﬂagged by the CS-5100.
Interference of lipids on hemostatic assays is supposed to be signiﬁcant at > 150 mg/dL triglyceride [4]. All four selected lipemic
samples, were conﬁrmed by measurement of triglycerides as > 400 mg/dL. The CS-5100 ﬂagged all samples but one. The
concentration of triglyceride in this sample was extremely high (943 mg/dL). This discrepancy may be caused by the fact that lipids
vary greatly in size and composition, and thus true triglyceride concentrations do not always correlate with the results from
photometric interference detection.
Fig. 1. Correlation of CS-5100 to CS-2000i for prothrombin time (PT) (A), partial thromboplastin time (PTT) (B), ﬁbrinogen (C) and antithrombin (D).
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3.4. Stress test
On the ﬁrst day of the stress test the analyzer had no problems with vial changes following used-up reagents or sample aspiration
with diﬀerent primary tubes and sample cups. STAT samples were given high priority when they were started. No major errors were
observed during the ﬁrst day instead of ﬂags because of used-up reagent or quality control results outside the target intervals.
On the second day of the stress test, throughput of the CS-5100 was compared to the ACL TOP and determined by the processing
times for testing 100 samples with a mixed assay proﬁle (PT, PTT, AT and D-dimer; 210 results). The results of the throughput study
are presented in Table 5. The ﬁrst result was shown by the ACL TOP analyzer after 6 min 10 s, whereas the CS-5100 ﬁnished the ﬁrst
sample after 8 min 28 s. For the measurement of all 100 samples, the CS-5100 was 38% faster (48 min 51 s) than the ACL TOP
(67 min 24 s). STAT capability was determined by the processing time of two STAT samples for the same four assays. Although the
CS-5100 required two minutes more to report the ﬁrst result, it completed the full job list (218 results) 18 min ahead of the ACL TOP
(27% faster). STAT processing was more than twice as fast with the CS-5100 compared to ACL TOP (55% faster).
Fig. 2. Bland-Altman plots for prothrombin time (PT) (A), partial thromboplastin time (PTT) (B), ﬁbrinogen (C) and antithrombin (AT) (D).
Table 4
Comparison of analyzers using Bland-Altman difference plots–summary of differences.
Test/unit Reagent CS-5100/CS-2000i CS-5100/ACL TOP
n Mean of diﬀerences (x–y) ± 2SD n Mean of diﬀerences (x–y) ± 2SD
PT [s] Dade Innovin 2147 0.325 (−0.691, 1.341) 2148 −1.332 (−5.933, 3.268)
Thromborel 1313 −0.324 (−1.392, 0.744) 1313 0.573(−6.765, 7.911)
PT [%] Dade Innovin 2220 −0.266 (−4.852, 4.320) 2210 −3.209 (−15.892, 9.474)
Thromborel 1313 −2.155 (−7.716, 3.405) 1313 −11.666 (−29.791, 6.459)
INR Dade Innovin 2220 0.006 (−0.072, 0.083) 2221 −0.081 (−0.400, 0.239)
Thromborel 1313 0.013 (−0.104, 0.129) 1313 0.088 (−0.405, 0.580)
PTT [s] Actin FSL 1637 −0.167 (−2.042, 1.708) 1637 −3.206 (−16.456, 10.043)
Pathromtin SL 1004 −0.643 (−4.031, 2,744) 1005 8.327 (−9.384, 26.038)
Fibrinogen Dade Thrombin Reagent 639 −0.007 (−0.306, 0.293) 641 0.374 (−0.188, 0.936)
Antithrombin INNOVANCE Antithrombin 255 −1.076 (−12.411, 10.260) 256 1.831 (−11.906, 15.567)
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The barcode reader showed very good functionality and was able to read e.g. distorted and crumpled barcodes. The problems in
reading the barcode occurred when the barcode was very wet or when it was overwritten with a pencil.
4. Discussion
This study compared the high-volume blood coagulation analyzer Sysmex CS-5100 System to the mid-volume blood coagulation
analyzer Sysmex CS-2000i System for analytical performance. Additionally, these data were compared to the high-volume blood
coagulation analyzer ACL TOP for operational performance.
The analytical performance for several assays on the CS-5100 was compared to that of the CS-2000i using the same Siemens
reagents on both systems. The agreement between the two CS-systems was excellent. We show here for the ﬁrst time a comparison of
the CS-5100 and the CS-2000i or the ACL TOP, which included evaluation of the analytical and technical performance. The inter-
assay CVs obtained were excellent at all concentrations measured. The results are similar to those obtained in other studies with fully
automated coagulation analyzers ACL TOP [5,6], Sysmex CA 6000 System [7] and Sysmex CA-7000 System [8].
As stated by the manufacturer, the CS-5100 has a higher throughput than the CS-2000i. Compared to the ACL TOP the CS-5100
showed considerably higher throughput while maintaining similar accuracy and imprecision.
For emergency (STAT) samples, a speciﬁc sampling position can be used which guarantees preferential treatment of the sample
and fast results during routine operations.
During the study, the CS-5100 stopped once while it was measuring a high concentration made up of FVIII, von Willebrand
factor antigen and INNOVANCE VWF Ac in a single blood sample taken from one patient. The cause of the stop was the fact that the
CS-5100 had taken an insuﬃcient volume of plasma aliquot from the total plasma sample. The device was thus unable to carry out a
second measurement. Remarkably, this was the only system failure during the entire study period of 4 months. Since then, the error
has been corrected by updating the software. Furthermore, no technical support was needed on site during the evaluation, showing
that the system is robust.
The analyzer enables real-time monitoring of each sample status on-board, the status of the on-board time of each reagent and
gives an overview of the number of tests that can be performed with this reagent volume. The software was extremely simple and
intuitive to use.
Performance under stress conditions (running the system under simulated/provoked stress conditions) and usability during high
throughput analysis were very good (data not shown).
Using the HIL check, the analyzer provides the routine technician with a fast and objective preanalytical sample check. However,
some limitations were evident in an extremely lipemic sample.
Overall, the CS-5100 is excellent in terms of user needs and requirements under routine operating conditions.
The Sysmex CS-2000i System is not available for sale in the USA. Product availability varies by country.
Actin, Berichrom, Ci-Trol, Dade, INNOVANCE, Innovin, Pathromtin, ProC and Thromborel are trademarks of Siemens
Healthcare Diagnostics Inc. or its aﬃliates.
Sysmex is a trademark of Sysmex Corporation.
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